L&S Knock-Out Zealand Pharma A/S/ DE000LX30PB7 /
11/15/2024 8:12:37 AM | Chg.-0.26 | Bid10:00:23 PM | Ask10:00:23 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
3.24EUR | -7.43% | - Bid Size: - |
- Ask Size: - |
- | 78.6075 EUR | 12/31/2078 | Call |
GlobeNewswire
8/22
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
GlobeNewswire
8/12
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial...
GlobeNewswire
6/26
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary share...
GlobeNewswire
6/25
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900...
GlobeNewswire
6/25
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 90...
GlobeNewswire
6/20
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose ...
GlobeNewswire
6/7
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improveme...
GlobeNewswire
6/7
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsenin...
GlobeNewswire
6/6
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial ...
GlobeNewswire
5/31
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire
5/29
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
GlobeNewswire
5/23
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low ...
GlobeNewswire
5/9
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial...
GlobeNewswire
3/20
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire
2/26
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated ...
GlobeNewswire
2/26
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver dise...